George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Imagine how amateurish it would look if they had to issue an rns to its lowlife pathetic shareholders to tell them everything is ok and we’ve fixed the problem!
Far to busy shrinking tumours and extending peoples lives than typing up rns’s to silly immature investors who genuinely have no idea what they are doing and should stay well clear of investing especially investing in a company like Avacta !
The avacta board had agreed to pay a man £300k a year.
A man of monumental power and experience in licensing deals all over planet Earth and people think it’s a goner 🤪🤪🤪🤪
This will climb like a monkey in a forest fire when the deal lands …make no mistake!!
Note: no monkeys were hurt in this experiment
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce the appointment of Dr Simon Bennett as Chief Business Officer of the Therapeutics Division.
Simon has over 26 years' commercial experience in the biopharma industry. He has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development. Simon has been involved in over 80 commercial deals across Europe, North America, Australasia, Japan, Russia/CIS and South America.
Only 4 from England
https://www.fda.gov/media/110742/download
Https://www.fda.gov/about-fda/2023-oce-annual-report/ongoing-clinical-oncology-projects